Stock 1093 CSPC PHARMACEUTICAL GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
6.6 HKD +1.23% Intraday chart for CSPC Pharmaceutical Group Ltd. +14.38% -9.09%
Apr. 26 CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 CI
Apr. 26 CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 115,871 94,800 100,932 97,707 86,022 78,175 - -
Enterprise Value (EV) 1 108,950 86,246 89,633 86,241 86,022 60,796 55,099 50,732
P/E ratio 28.5 x 15.4 x 14.7 x 14.1 x 13.5 x 11 x 10.2 x 9.35 x
Yield 1.08% 1.61% 2.13% 2.56% - 2.89% 3.16% 3.67%
Capitalization / Revenue 4.8 x 3.19 x 2.94 x 2.77 x 2.52 x 2.08 x 1.92 x 1.77 x
EV / Revenue 4.51 x 2.9 x 2.61 x 2.44 x 2.52 x 1.62 x 1.35 x 1.15 x
EV / EBITDA 18.8 x 10.5 x 9.5 x 9.43 x 9.99 x 6.04 x 5.05 x 4.12 x
EV / FCF 52.1 x 13.5 x 23.7 x 14.1 x - 9.12 x 8.33 x 7.51 x
FCF Yield 1.92% 7.43% 4.22% 7.11% - 11% 12% 13.3%
Price to Book 5.74 x 3.55 x 3.17 x 2.86 x - 1.9 x 1.66 x 1.46 x
Nbr of stocks (in thousands) 11,973,770 11,954,570 11,916,370 11,915,520 11,848,756 11,844,632 - -
Reference price 2 9.677 7.930 8.470 8.200 7.260 6.600 6.600 6.600
Announcement Date 3/30/20 3/15/21 3/22/22 3/22/23 3/20/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,145 29,762 34,309 35,292 34,175 37,591 40,686 44,104
EBITDA 1 5,789 8,192 9,431 9,148 8,615 10,058 10,901 12,305
EBIT 1 5,025 7,227 8,366 7,952 7,400 8,762 9,370 10,346
Operating Margin 20.81% 24.28% 24.38% 22.53% 21.65% 23.31% 23.03% 23.46%
Earnings before Tax (EBT) 1 5,053 7,626 8,430 8,650 8,030 8,918 9,600 10,467
Net income 1 4,057 6,157 6,901 6,949 6,382 7,128 7,691 8,402
Net margin 16.8% 20.69% 20.11% 19.69% 18.68% 18.96% 18.9% 19.05%
EPS 2 0.3394 0.5150 0.5773 0.5831 0.5376 0.5993 0.6448 0.7058
Free Cash Flow 1 2,090 6,404 3,787 6,129 - 6,667 6,614 6,752
FCF margin 8.66% 21.52% 11.04% 17.37% - 17.74% 16.26% 15.31%
FCF Conversion (EBITDA) 36.11% 78.17% 40.15% 67% - 66.28% 60.67% 54.87%
FCF Conversion (Net income) 51.52% 104.01% 54.87% 88.2% - 93.53% 85.99% 80.35%
Dividend per Share 2 0.1042 0.1275 0.1800 0.2100 - 0.1910 0.2087 0.2422
Announcement Date 3/30/20 3/15/21 3/22/22 3/22/23 3/20/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 8,328 8,895 - 8,883 8,634 8,489 17,479 8,938 8,626 8,522 8,242 8,878 9,067 9,890 10,021
EBITDA 2,330 - - - - - - - - - - - - - -
EBIT 1 2,074 2,380 - 1,871 1,830 1,928 3,697 2,000 2,051 1,865 1,517 1,959 2,034 2,147 2,202
Operating Margin 24.9% 26.76% - 21.07% 21.19% 22.72% 21.15% 22.38% 23.78% 21.88% 18.41% 22.06% 22.43% 21.71% 21.98%
Earnings before Tax (EBT) - - - - - 2,265 4,379 1,977 2,139 2,111 1,934 - - - -
Net income 1,554 1,563 1,657 1,793 1,644 1,852 3,543 1,586 1,653 1,672 1,498 - - - -
Net margin 18.66% 17.58% - 20.19% 19.04% 21.82% 20.27% 17.74% 19.16% 19.62% 18.18% - - - -
EPS 2 0.1299 0.1309 0.1391 0.1504 0.1380 0.1554 0.2990 0.1331 0.1393 0.1410 0.1265 0.1410 0.1410 0.1520 0.1520
Dividend per Share 2 - 0.1000 - 0.1000 - 0.1100 - - 0.1400 - - - - - 0.1680
Announcement Date 11/18/21 3/22/22 5/25/22 8/24/22 11/23/22 3/22/23 3/22/23 5/25/23 8/23/23 11/30/23 3/20/24 - - - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 6,922 8,554 11,298 11,467 - 17,378 23,076 27,443
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,090 6,404 3,787 6,129 - 6,667 6,614 6,752
ROE (net income / shareholders' equity) 22.2% 25.3% 23.2% 21.7% - 18.3% 17.7% 17.4%
ROA (Net income/ Total Assets) 15% 18.3% 17.3% 16% - 13.4% 13.4% 13.1%
Assets 1 27,066 33,643 39,898 43,540 - 53,285 57,400 64,268
Book Value Per Share 2 1.690 2.230 2.670 2.870 - 3.480 3.980 4.510
Cash Flow per Share 2 0.3500 0.6700 0.4800 0.7300 - 0.8500 0.7700 0.8800
Capex 1 2,049 1,613 1,914 2,517 - 2,040 2,060 2,235
Capex / Sales 8.48% 5.42% 5.58% 7.13% - 5.43% 5.06% 5.07%
Announcement Date 3/30/20 3/15/21 3/22/22 3/22/23 3/20/24 - - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for CSPC Pharmaceutical Group Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
6.6 HKD
Average target price
9.348 HKD
Spread / Average Target
+41.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CSPC PHARMACEUTICAL GROUP LTD. Stock CSPC Pharmaceutical Group Ltd.
-9.09% 9.99B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1093 Stock
  4. Financials CSPC Pharmaceutical Group Ltd.